Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00060684 | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | completed | Phase 1 | 30 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT01219010 | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | completed | Phase 1 | 30 | Janssen Research & Development, LLCINDUSTRY | 3 | Jan 19, 2015 |
| clinicaltrials |
| NCT00274742 | Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | completed | Phase 1 | 76 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 16, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00665990 | Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | completed | Phase 1 | 49 | St. Jude Children's Research HospitalOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT00323934 | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00324129 | A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes | completed | Phase 1 | 29 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00324194 | A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 25 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00078637 | Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma | completed | Phase 1 | 37 | Eisai Inc.INDUSTRY | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00082784 | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | completed | Phase 1 | 93 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT01035216 | A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) | terminated | Phase 1 | 18 | SBI Biotech Co., Ltd.INDUSTRY | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01132586 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01330173 | Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00079716 | Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma | completed | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00103779 | A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 50 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00283101 | A Safety Study in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 12 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00283114 | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 82 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00430846 | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | completed | Phase 1 | 45 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00649584 | A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00655837 | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | completed | Phase 1 | 33 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01015911 | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | completed | Phase 1 | 58 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01026415 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | completed | Phase 1 | 73 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | completed | Phase 1 | 51 | Seagen Inc.INDUSTRY | 2 | Dec 18, 2014 | clinicaltrials |
| NCT01026233 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | completed | Phase 1 | 52 | Seagen Inc.INDUSTRY | 2 | Dec 12, 2014 | clinicaltrials |
| NCT00968656 | Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1(FISO PET/CT) | completed | Phase 1 | 31 | Washington University School of MedicineOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | terminated | Phase 1 | 3 | John MascarenhasOTHER | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00460421 | A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT | completed | Phase 1 | 27 | Swedish Orphan BiovitrumINDUSTRY | 1 | Dec 5, 2014 | clinicaltrials |
| NCT01431664 | AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 7 | Cancer Research UKOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01561911 | A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | completed | Phase 1 | 29 | Cancer Research UKOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00668421 | CEP-701 (Lestaurtinib) in Myelofibrosis | unknown | Phase 1 / Phase 2 | 60 | Ronald HoffmanOTHER | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00991562 | IMGN901 in Combination With Lenalidomide and Dexamethasone | completed | Phase 1 | 50 | ImmunoGen, Inc.INDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT02238522 | Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | withdrawn | Phase 1 | 0 | Zenith EpigeneticsINDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00727766 | Oral Clofarabine for Acute Myeloid Leukemia | completed | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Nov 11, 2014 | clinicaltrials |
| NCT00703300 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Nov 7, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00891137 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | completed | Phase 1 | 30 | Cellerant TherapeuticsINDUSTRY | 1 | Oct 27, 2014 | clinicaltrials |
| NCT00070616 | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support | completed | Phase 1 | 25 | Swedish Orphan BiovitrumINDUSTRY | 0 | Oct 24, 2014 | clinicaltrials |
| NCT02274584 | CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) | unknown | Phase 1 / Phase 2 | 20 | Peking UniversityOTHER | 2 | Oct 24, 2014 | clinicaltrials |
| NCT01164163 | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | completed | Phase 1 | 49 | Children's Oncology GroupNETWORK | 1 | Oct 23, 2014 | clinicaltrials |
| NCT02247609 | Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas(4SCAR19273) | unknown | Phase 1 / Phase 2 | 20 | Peking UniversityOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00349596 | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | completed | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00525447 | Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 | 36 | Seagen Inc.INDUSTRY | 1 | Oct 9, 2014 | clinicaltrials |
| NCT01919866 | Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells | unknown | Phase 1 / Phase 2 | 120 | University Children's Hospital TuebingenOTHER | 2 | Oct 8, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01751919 | A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | completed | Phase 1 | 37 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Oct 1, 2014 | clinicaltrials |
| NCT02248402 | Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma(Vax-DC/MM) | unknown | Phase 1 / Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01504776 | Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)(BUS48T) | completed | Phase 1 | 3 | Anand JillellaOTHER | 1 | Sep 19, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Jan 19, 2015source: clinicaltrials